AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global Neuroendocrine Tumors Therapeutics Market 2019-2023: The Advent of Radiolabeled Drugs - ResearchAndMarkets.com

May 8, 2019

DUBLIN--(BUSINESS WIRE)--May 8, 2019--The “Global Neuroendocrine Tumors Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

Increasing research grants and funding are contributing to the neuroendocrine tumors therapeutics market growth in the forthcoming years. Various government and non-government organizations are focusing on providing grants and funding to create an awareness about neuroendocrine tumors. These programs also help in better and quicker development of therapies for the treatment of neuroendocrine tumors. Furthermore, the grants are expected to accelerate the research and strengthen the drug development pipeline of neuroendocrine tumors, thus, impacting the market growth positively over the next few years. The analysts have predicted that the neuroendocrine tumors therapeutics market will register a CAGR of close to 9% by 2023.

One of the growth drivers of the global neuroendocrine tumor’s therapeutics market is the advent of radiolabeled drugs. Due to their high efficacy with less adverse effects, such novel drugs receive high adoption from medical practitioners, which broadens the overall patient base and drives the market growth.

One of the challenges in the growth of the global neuroendocrine tumor’s therapeutics market is the increasing preference for alternative treatments. Therapeutic approaches remain costly, more time consuming, and non-remissive in nature, which makes them less preferred treatment options among patients as well as medical practitioners, which poses a challenge to market growth.

The market appears to be highly concentrated with the presence of a few market players. Vendors are focusing on extensive research for identifying the attributes of neuroendocrine tumors through a genomic approach, as the identification of mutated genes is one of the biggest challenges for developing target therapies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • Preface
  • Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Somatostatin analogs - Market size and forecast 2018-2023
  • Targeted therapies - Market size and forecast 2018-2023
  • Other therapies - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd
  • Ipsen Pharma
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.

For more information about this report visit https://www.researchandmarkets.com/r/iesv6g

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005351/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/08/2019 05:43 AM/DISC: 05/08/2019 05:43 AM

http://www.businesswire.com/news/home/20190508005351/en